A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)

A Double-Blind, Randomized, 2-Period Crossover, Placebo Controlled Study to Asses the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MK0822

This study will assess the safety and tolerability of single doses of odanacatib (MK0822) when administered with a light breakfast.

Inclusion Criteria:

• Subject is male and between the ages of 18 and 45
• Subject is within 25% of ideal body weight and weighs between 55 and 95 kg
• Subject is in generally good health
• Subject is a nonsmoker

Exclusion Criteria:

• Subject has multiple or severe allergies to food or medications
• Subject has a history of metabolic bone disease, kidney/bladder stones, or treatment with bisphosphonates
• Subject has any infections, including HIV
• Subject has donated blood or taken another investigational drug in the last month
• Subject consumes excessive amounts of caffeine or alcohol
• Subject has a history of any illness that may confound the results of the study or pose additional risk in administering the study drug